ArticleJournal of translational medicine2023
Pharmacological inhibition of demethylzeylasteral on JAK-STAT signaling ameliorates vitiligo.
Article in Journal of translational medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 26 citations in OpenAlex.
- JAK inhibitor tofacitinib alleviates secretory dysfunction and Th17/Treg imbalance in a Sjögren's disease murine model.Annals of medicine · 2026Article
- Pharmacological Mechanisms of Active Constituents from Traditional Chinese Medicine for Vitiligo Treatment.Pharmaceuticals (Basel, Switzerland) · 2026Review
- The JAK/STAT pathway: a pivotal therapeutic target in disease and advances in natural product modulation.Molecular diversity · 2026Review
- Combining bioinformatics prediction with experimental validation to explore the ameliorative effect ofMolecular medicine reports · 2026Article
- Review
- Exploring the impact of IL-2 cytokine family on skin barrier function: pathophysiology and therapeutic strategies.Molecular biology reports · 2026Review
- Gut and skin microbiome-metabolome pathways in vitiligo: from dysbiosis to immune activation and melanocyte dysfunction.Frontiers in immunology · 2026Review
- APOE deficiency triggers anti-tumour activity of macrophages in liver cancer.Cancer gene therapy · 2025Article
- Filiform fire needling therapy relieves T cells-mediated melanocyte apoptosis and dysfunction by inhibiting JAK/STAT3 pathway via Mfsd4a in vitiligo.Chinese medicine · 2025Article
- Leflunomide-Mediated Immunomodulation Inhibits Lesion Progression in a Vitiligo Mouse Model.International journal of molecular sciences · 2025Article
- Large Language Models in Integrative Medicine: Progress, Challenges, and Opportunities.Journal of evidence-based medicine · 2025Review
- Structural diversity and biological activities of terpenoids derived fromRSC advances · 2025Review
- Local sympathetic nerve depletion does not alter vitiligo progression in a mouse model.Frontiers in medicine · 2025Article
- LL37-driven mast cell degranulation and inflammation in rosacea via TLR2/JAK2/STAT3 axis.Frontiers in immunology · 2025Article
- The Anti-Vitiligo Effects of Feshurin In Vitro fromPharmaceuticals (Basel, Switzerland) · 2024Article
- The Art of Finding the Right Drug Target: Emerging Methods and Strategies.Pharmacological reviews · 2024Review
- Selection signatures of wool color in Gangba sheep revealed by genome-wide SNP discovery.BMC genomics · 2024Article
- An Overview of the Biological Complexity of Vitiligo.Oxidative medicine and cellular longevity · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe activation of CD8
methodsThe efficacy of T-96 was tested in our mouse model of vitiligo, and the numbers of CD8
resultsHere, we found that T-96 reduced CD8
conclusionOur findings demonstrated that T-96 might have positive therapeutic responses to vitiligo by pharmacologically inhibiting the effector functions and skin trafficking of CD8
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.